公开(公告)号：EP0692930A4

公开(公告)日：1998-04-01

申请号：EP94910879

申请日：1994-03-07

申请人： ISIS PHARMACEUTICALS INC

发明人： DRAPER KENNETH G ,  CROOKE STANLEY T ,  MIRABELLI CHRISTOPHER K ,  ECKER DAVID J ,  HANECAK RONNIE C ,  ANDERSON KEVIN P ,  BROWN-DRIVER VICKIE L ,  WYATT JACQUELINE R

IPC分类号： C12N15/09 ,  A61K31/70 ,  A61K31/7088 ,  A61K38/00 ,  A61P31/12 ,  A61P31/22 ,  C07H21/00 ,  C07H21/04 ,  C07K14/03 ,  C12N15/113 ,  C12N15/117 ,  C12Q1/70 ,  A01N43/04 ,  C07H17/00

CPC分类号： C12N15/1133 ,  A61K31/70 ,  A61K38/00 ,  C07H21/00 ,  C07K14/005 ,  C12N15/1137 ,  C12N15/117 ,  C12N2310/151 ,  C12N2310/18 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/33 ,  C12N2310/346 ,  C12N2310/3517 ,  C12N2310/3521 ,  C12N2710/16622 ,  C12Q1/701 ,  C12Y207/07049 ,  C12Y301/01004

摘要： Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

公开(公告)号：EP1035870A4

公开(公告)日：2003-01-02

申请号：EP98960818

申请日：1998-12-08

申请人： ISIS PHARMACEUTICALS INC

发明人： ANDERSON KEVIN P ,  HANECAK RONNIE C ,  NOZAKI CHIKATERU

IPC分类号： C12N15/09 ,  A61K31/711 ,  A61K38/00 ,  A61K38/21 ,  A61K48/00 ,  A61P1/16 ,  A61P31/20 ,  C07H21/04 ,  C07K14/18 ,  C12N15/113 ,  C12Q1/70 ,  C12Q1/68

CPC分类号： C12N15/1131 ,  A61K38/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/318 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3233 ,  C12N2310/33 ,  C12N2310/334 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2770/24222 ,  C12Q1/707 ,  C12N2310/3525 ,  C12N2310/3527 ,  C12N2310/3521

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

公开(公告)号：EP0672193A4

公开(公告)日：1995-11-22

申请号：EP93922788

申请日：1993-09-29

申请人： ISIS PHARMACEUTICALS INC

发明人： HANECAK RONNIE C ,  ANDERSON KEVIN P ,  BENNETT C FRANK ,  CHIANG MING-YI ,  BROWN-DRIVER VICKIE L ,  ECKER DAVID J ,  VICKERS TIMOTHY A ,  WYATT JACQUELINE R ,  IMBACH JEAN LOUIS IMPASSE DES

IPC分类号： C12N15/09 ,  A01N63/00 ,  A61K31/70 ,  A61K38/00 ,  A61P31/12 ,  A61P31/16 ,  A61P35/00 ,  C07H21/00 ,  C07H21/04 ,  C12N15/113 ,  C12N15/115 ,  C12N15/117 ,  C12P19/34 ,  C12Q1/68 ,  C12Q1/70 ,  A01N43/04 ,  C07H15/12 ,  C07H17/00

CPC分类号： A61K31/70 ,  A61K38/00 ,  C07H21/00 ,  C12N15/1133 ,  C12N15/1137 ,  C12N15/115 ,  C12N15/117 ,  C12N2310/151 ,  C12N2310/18 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/346 ,  C12Q1/701 ,  C12Y207/07049 ,  C12Y301/01004 ,  C12N2310/3521

摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

摘要翻译： 提供了具有保守的G4序列和足够数量的侧翼核苷酸以显着抑制诸如HSV-1或磷脂酶A2的病毒的活性或调节染色体的端粒长度的经修饰的寡核苷酸。 还提供G4四重子寡核苷酸结构。 还提供了用于病毒相关疾病和与磷脂酶A2水平升高相关的疾病的预防，诊断和治疗的方法。 还提供了调节染色体端粒长度的方法; 据信端粒长度的调节在细胞的老化过程和恶性细胞生长的控制中起作用。